Helicid Neo

Helicid Neo is a pharmaceutical product that contains the proton‑pump inhibitor omeprazole as its sole active ingredient. It is supplied in oral dosage form, with the specific strength not disclosed in the available data. Marketed in the European Union, Helicid Neo belongs to the acid‑reducer therapeutic class and is intended for use under the guidance of a healthcare professional and may be prescribed for several gastrointestinal conditions.

Helicid Neo (omeprazole) is indicated for the management of acid‑related gastrointestinal disorders.

- Relief of symptoms and mucosal healing in gastroesophageal reflux disease (GERD), including heartburn and acid regurgitation. - Induction of healing in erosive esophagitis caused by chronic acid exposure. - Treatment of active duodenal and gastric ulcers, promoting ulcer closure and symptom control. - Inclusion in multi‑drug regimens for Helicobacter pylori eradication to improve eradication rates. - Prevention of NSAID‑induced gastric ulcer recurrence in patients requiring long‑term NSAID therapy.

Like other proton‑pump inhibitors, Helicid Neo may be associated with a range of adverse effects, most of which are mild and reversible.

Common: - Headache. - Diarrhea or loose stools. - Abdominal pain or dyspepsia. - Nausea.

Serious: - Severe allergic reactions such as rash, itching, swelling, or difficulty breathing. - Clostridioides difficile‑associated colitis. - Low magnesium levels (hypomagnesemia) with prolonged use.

Before starting Helicid Neo, certain precautionary measures should be considered to ensure safe and effective use.

- Assess for known hypersensitivity to omeprazole or other proton‑pump inhibitors. - Use with caution in patients with severe liver impairment, as drug clearance may be reduced. - Evaluate the need for long‑term therapy, especially in older adults, because prolonged use can affect nutrient absorption. - Consider potential risk of bone fractures with extended treatment duration. - Monitor for signs of infection, such as persistent diarrhea, which may indicate C. difficile overgrowth. - Discuss pregnancy and breastfeeding status with a healthcare provider, as safety data are limited.

Helicid Neo can interact with several medicines; recognizing these interactions helps avoid reduced efficacy or increased toxicity.

Avoid: - Concomitant use with atazanavir or nelfinavir, where omeprazole markedly reduces antiviral absorption. - Co‑administration with rilpivirine, which may lower its plasma concentrations.

Use with caution: - Antiplatelet agents such as clopidogrel, where omeprazole may diminish antiplatelet effect. - Warfarin, as omeprazole can increase INR and bleeding risk. - Methotrexate, especially high‑dose regimens, due to possible reduced renal clearance. - Digoxin, where increased serum levels have been reported.